The supply chain for a high-value functional ingredient often begins with a fragile agricultural crop, a complex chemical synthesis, or a geopolitical bottleneck. Anomaly Bio is betting it can start with a sugar feedstock and a precisely engineered microbe instead. The Singapore-based startup, founded in 2025, raised a $2.6 million pre-seed round to build what it calls micro-factories, using advanced fermentation and strain engineering to produce bio-based molecules for nutrition, agriculture, and personal care [TechNode Global, Nov 2025]. The round was led by Pebblebed Ventures and included angels like Notion's Akshay Kothari and Solugen co-founder Sean Hunt, signaling early conviction in a technical team still establishing its first lab [Anomaly Bio blog, Nov 2025].
The technical wedge: fermentation as infrastructure
At its core, Anomaly Bio is an infrastructure play for ingredient manufacturing. The company's stated goal is to replace extractive or chemically intensive processes with a biological one, programming microbes to convert sugars into target molecules through fermentation [Preqin]. This is not a novel concept in synthetic biology, but its application across fragmented markets like crop protection and nutraceuticals represents a specific wedge. The bet is that a flexible biomanufacturing platform can out-compete on cost, purity, and supply resilience for a range of B2B customers, particularly in North America and Europe [Preqin]. The $2.6 million in new capital is earmarked for establishing lab and pilot facilities in Singapore, moving from concept to tangible strain development and yield optimization [TechNode Global, Nov 2025].
A founding team built on prior iteration
Co-founders Samyak Baid and Armaan Dhanda are not new to building in the bioeconomy. They previously launched Pawsible Foods, a venture focused on sustainable pet nutrition, giving them direct exposure to ingredient sourcing and formulation challenges [Crunchbase]. Both studied at the National University of Singapore (NSU), where they led the Alt Protein Project group, and they have already secured non-dilutive support, including a $25,000 grant from Nikhil Kamath's WTFund and a win at the 2025 MIT Water, Food & Agriculture Innovation Prize [Anomaly Bio blog; Good Food Institute]. This track record of securing early-stage capital and recognition appears to have smoothed the path for their institutional pre-seed.
The investor syndicate brings a blend of venture capital and operational expertise.
| Investor | Notable Affiliation | Rationale (Inferred) |
|---|---|---|
| Pebblebed Ventures | Lead VC | Early-stage deep tech focus in Asia. |
| Akshay Kothari | Co-founder, Notion | Product-building and scaling experience. |
| Sean Hunt | Co-founder, Solugen | Direct experience in industrial biomanufacturing at scale. |
| Eben Bayer | Co-founder, Ecovative | Expertise in mycelium-based biomaterials. |
| Mithun Sacheti | Founder, CaratLane | Supply chain and branding in premium goods. |
The scale-up equation and its unknowns
The company is pre-revenue and pre-product, with no disclosed customers or partnerships beyond academic support from NSU [TechNode Global, Nov 2025]. The next 12 months will be a pure R&D build phase. The technical and commercial risks are significant and interlinked.
- Strain performance. The core hypothesis rests on engineering microbes that produce target molecules at yields high enough to be economically viable. This is a multivariate optimization problem spanning genetic design, fermentation conditions, and downstream processing. Missed milestones here delay everything.
- Unit economics at pilot scale. Moving from a lab flask to a pilot bioreactor introduces new cost and engineering challenges. The cost per kilogram of output at this intermediate scale will be the first real indicator of commercial potential.
- Regulatory and customer adoption. Even with a successful pilot, ingredients for nutrition and agriculture face stringent regulatory pathways. Concurrently, the sales motion requires convincing large, conservative B2B buyers to switch from established supply chains to a novel, bio-based source.
A short technical breakdown: the company's approach likely involves selecting a host microbe (like yeast or bacteria), using genetic tools to insert pathways for producing a specific compound, and then iteratively improving yield through directed evolution or metabolic engineering. The real test comes in translating lab-optimized strains to larger fermentation tanks, where factors like oxygen transfer, heat management, and byproduct inhibition can drastically reduce output.
The sober assessment is that the capital raised, while substantial for a pre-seed, is a down payment on a long and capital-intensive journey. The founders' previous venture provides relevant experience but not necessarily in the hard tech of strain engineering at production scale. Success depends on navigating the infamous "valley of death" between promising lab results and a commercially viable manufacturing process. If Anomaly Bio can demonstrate compelling yield data from its new Singapore lab in the coming year, it will have earned the right to a much larger, and more challenging, Series A.
Sources
- [Anomaly Bio blog, Nov 2025] Singapore's Anomaly Bio raises US$2.6M to turn microbes into micro-factories | https://www.anomalybio.com/blog/singapore-s-anomaly-bio-raises-us-2-6m-to-turn-microbes-into-micro-factories-for-resilient-ingredient-supply-chains
- [TechNode Global, Nov 2025] Singapore's Anomaly Bio raises $2.6M in pre-seed funding led by Pebblebed Ventures | https://technode.global/2025/11/12/singapores-anomaly-bio-raises-2-6m-in-funding-led-by-pebblebed-ventures/
- [Preqin] Anomaly Bio company profile | https://www.preqin.com/data/profile/asset/anomaly-bio/777565
- [Crunchbase] Anomaly Bio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/anomaly-bio
- [Good Food Institute] Impact stories of the Alt Protein Project | https://gfi.org/alt-protein-project-impact/
- [e27, Nov 2025] Anomaly Bio powers the future of ingredient manufacturing with US$2.6M in pre-seed funding | https://e27.co/anomaly-bio-powers-the-future-of-ingredient-manufacturing-with-us2-6m-in-pre-seed-funding-20251112/